RNF130 Inhibitors
Chemical inhibitors of RNF130 can function by indirectly targeting the protein degradation pathway in which RNF130 plays a critical role as an E3 ubiquitin-protein ligase. Proteasome inhibitors like MG-132, Lactacystin, Epoxomicin, Bortezomib, Carfilzomib, Ixazomib, Oprozomib, Delanzomib, and Marizomib work by preventing the proteasome from degrading ubiquitinated proteins. This inhibition leads to an accumulation of the proteins tagged for degradation by RNF130, which can result in a functional blockade of RNF130 activity. The accumulated ubiquitinated proteins can bind to RNF130, reducing its ability to interact with and ubiquitinate new substrates, effectively inhibiting its enzymatic function. This buildup can lead to a state where RNF130 is overwhelmed by its substrates, which in turn, may decrease the effective ubiquitination of target proteins by RNF130.
Further, the ubiquitin-specific protease inhibitor Pyrimidopyrimidone targets a different aspect of the protein degradation cycle. Moreover, Nelfinavir, although primarily known for other indications, has been found to have inhibitory effects on the proteasome. This inhibition can lead to a similar outcome as other proteasome inhibitors, where the function of RNF130 is inhibited due to the increased levels of ubiquitinated substrates within the cell. These substrates compete for RNF130's attention, thus impeding its ability to ubiquitinate additional proteins and fulfill its role in protein regulation. By targeting these mechanisms, the selected chemicals can reduce the functional activity of RNF130 within the cellular environment, leading to an inhibition of its protein regulatory actions.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
MG-132 is a proteasome inhibitor that can indirectly inhibit RNF130 by preventing the degradation of proteins ubiquitinated by RNF130, leading to a buildup of these substrates, which can sequester RNF130 and reduce its availability to ubiquitinate other proteins, thus functionally inhibiting RNF130 activity. | ||||||
Lactacystin | 133343-34-7 | sc-3575 sc-3575A | 200 µg 1 mg | $165.00 $575.00 | 60 | |
Lactacystin inhibits the proteasome's proteolytic function, which could lead to an accumulation of RNF130's substrates. This accumulation might inhibit RNF130's activity by competitive inhibition, where the excessive presence of substrate hinders RNF130's ability to interact with new substrates. | ||||||
Epoxomicin | 134381-21-8 | sc-201298C sc-201298 sc-201298A sc-201298B | 50 µg 100 µg 250 µg 500 µg | $134.00 $215.00 $440.00 $496.00 | 19 | |
Epoxomicin is a specific proteasome inhibitor, which can indirectly inhibit RNF130 by blocking the degradation pathway of ubiquitinated proteins, potentially leading to a negative feedback mechanism where an excess of ubiquitinated proteins might bind to RNF130 and inhibit its enzymatic activity. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib, another proteasome inhibitor, can indirectly inhibit RNF130 by disrupting the degradation of ubiquitin-tagged proteins, leading to substrate accumulation. This could cause substrate-induced inhibition of RNF130, as the enzyme becomes overwhelmed or misregulated by its substrates. | ||||||
Carfilzomib | 868540-17-4 | sc-396755 | 5 mg | $40.00 | ||
Carfilzomib irreversibly inhibits the proteasome, potentially leading to an indirect inhibition of RNF130. The buildup of ubiquitinated proteins destined for degradation might lead to a non-functional saturation of RNF130, thereby decreasing its effective enzymatic activity. | ||||||
Ixazomib | 1072833-77-2 | sc-489103 sc-489103A | 10 mg 50 mg | $311.00 $719.00 | ||
Ixazomib selectively inhibits the proteasome, which can indirectly inhibit RNF130 by causing an accumulation of ubiquitinated proteins. This accumulation could inhibit the ubiquitin ligase activity of RNF130 by saturating the enzyme with its products, which in turn prevents the binding and ubiquitination of new substrates. | ||||||
Oprozomib | 935888-69-0 | sc-477447 | 2.5 mg | $280.00 | ||
Oprozomib is a proteasome inhibitor that can indirectly inhibit RNF130 by increasing the levels of ubiquitinated proteins, potentially leading to an inhibitory effect on RNF130's ligase activity as the enzyme becomes occupied with an excess of ubiquitinated substrates. | ||||||
Delanzomib, free base | 847499-27-8 | sc-396774 sc-396774A | 5 mg 10 mg | $160.00 $300.00 | ||
Delanzomib is a proteasome inhibitor that may indirectly inhibit RNF130 through the accumulation of ubiquitin-conjugated proteins, which could create a feedback inhibition mechanism where RNF130 is functionally inhibited by the elevated presence of its reaction products. | ||||||
Nelfinavir | 159989-64-7 | sc-507314 | 10 mg | $168.00 | ||
Nelfinavir, while primarily an antiretroviral drug, has been shown to inhibit the proteasome. This can lead to an indirect inhibition of RNF130 by causing an overload of ubiquitinated proteins within the cell, which may inhibit the ubiquitin ligase activity of RNF130 through competitive or feedback inhibition mechanisms. | ||||||